课题基金 / 基金详情

SCH 56592 IN TREATMENT OF AZOLE REFRACTORY CANDIDIASIS IN HIV

SCH 56592 IN TREATMENT OF AZOLE REFRACTORY CANDIDIASIS IN HIV
SCH 56592 治疗 HIV 中唑类难治性念珠菌病
批准号：
6265122
负责人：
L JOSEPH WHEAT
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265122
关键词：
AIDS therapy HIV infections antifungal agents candidiasis clinical research drug screening /evaluation esophagus disorder human subject human therapy evaluation microorganism disease chemotherapy oral administration oral pharyngeal disorder triazoles

项目摘要

项目成果

L JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is an open label, Phase III, multicenter study of SCH 56592 oral suspension in the treatment of oral and/or esophageal candidiasis. Subjects will be given SCH 56592 oral suspension for an initial treatment phase of 4 weeks. Subjects who respond clinically and are free of signs and symptoms after the 4 week treatment phase will be offered maintenance therapy with SCH 56592. Maintenance therapy will consist of SCH 56592 oral suspension 400 mg, b.i.d., three times per week for 3 months.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ADEFOVIR DIPIVOXIL, INDINAVIR, ZIDOVUDINE, LAMIVUDINE IN VARIOUS DOSE
SAQUINAVIR SOFT GEL CAP TID IN COMBO W/ 2 NRTS VS SAQUINAVIR BID IN H
L 743,872 VS AMPHOTERICIN B IN FLUCONAZOLE UNRESPONSIVE CANDIDIASIS
SP 303 FOR TREATMENT OF AIDS ASSOCIATED DIARRHEA
海外基金